Related Experiment Videos
Palivizumab for preterm infants. Is it worth it?
N D Embleton1, C Harkensee, M C Mckean
1Newcastle Neonatal Service, Department of Child Health, University of Newcastle upon Tyne, Royal Victoria Infirmary, Newcastle upon Tyne NE1 4LP, UK. n.d.embleton@ncl.ac.uk
Summary
Palivizumab prophylaxis for respiratory syncytial virus (RSV) in preterm infants shows limited benefits, with no proven cost-effectiveness in the UK. Further economic assessment is needed for high-risk infants.
Area of Science:
- Pediatrics
- Infectious Diseases
- Health Economics
Background:
- Respiratory syncytial virus (RSV) infection causes significant infant morbidity.
- Palivizumab prophylaxis is a common intervention, but its cost-effectiveness is debated.
- Preterm infants are a high-risk group for severe RSV outcomes.
Purpose of the Study:
- To systematically review the safety, efficacy, and cost-effectiveness of palivizumab prophylaxis for preterm infants in the UK.
- To evaluate the economic justification for current palivizumab usage.
- To inform clinical and policy decisions regarding RSV prevention.
Main Methods:
- Systematic literature search for randomized controlled trials and economic studies.
- Focused on palivizumab prophylaxis in preterm infants within the United Kingdom.
- Analysis of safety, efficacy (hospital admissions, serious outcomes), and cost-effectiveness data.
Main Results:
- One randomized controlled trial showed reduced hospital admissions but no improvement in severe outcomes.
- No UK-based cost studies demonstrated economic benefit for palivizumab prophylaxis.
- Evidence suggests limited overall benefit relative to cost.
Conclusions:
- Current evidence does not strongly support the cost-effectiveness of palivizumab prophylaxis for preterm infants in the UK.
- While potentially justifiable for high-risk infants, a comprehensive economic assessment is lacking.
- The high cost of new treatments necessitates rigorous economic evaluation.